INMB Insider Trading

Insider Ownership Percentage: 35.20%
Insider Buying (Last 12 Months): $236,436.60
Insider Selling (Last 12 Months): $0.00

INmune Bio Insider Trading History Chart

This chart shows the insider buying and selling history at INmune Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

INmune Bio Share Price & Price History

Current Price: $7.42
Price Change: Price Decrease of -0.386 (-4.94%)
As of 04/1/2025 03:39 PM ET

This chart shows the closing price history over time for INMB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$7.81Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for INmune Bio (NASDAQ:INMB)

12.72% of INmune Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INMB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$12Mbought$242ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
INmune Bio logo
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Read More on INmune Bio

Today's Range

Now: $7.42
Low: $7.33
High: $7.95

50 Day Range

MA: $8.43
Low: $6.53
High: $10.48

52 Week Range

Now: $7.42
Low: $4.32
High: $12.72

Volume

156,033 shs

Average Volume

244,224 shs

Market Capitalization

$197.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Who are the company insiders with the largest holdings of INmune Bio?

INmune Bio's top insider shareholders include:
  1. Raymond Joseph Tesi (CEO)
  2. David J Moss (CFO)
  3. Timothy J Schroeder (Director)
  4. Scott Juda (Director)
Learn More about top insider investors at INmune Bio.

Who are the major institutional investors of INmune Bio?

INmune Bio's top institutional investors include:
  1. Raymond James Financial Inc. — 2.15%
  2. Raymond James Financial Inc. — 2.15%
  3. Geode Capital Management LLC — 1.64%
  4. Millennium Management LLC — 1.31%
  5. Dauntless Investment Group LLC — 0.87%
  6. Renaissance Technologies LLC — 0.84%
Learn More about top institutional investors of INmune Bio stock.

Which institutional investors are selling INmune Bio stock?

Within the previous quarter, INMB stock was sold by these institutional investors:
  1. Citadel Advisors LLC
  2. Marshall Wace LLP

Which institutional investors are buying INmune Bio stock?

Within the last quarter, INMB stock was purchased by institutional investors including:
  1. Raymond James Financial Inc.
  2. Raymond James Financial Inc.
  3. Dauntless Investment Group LLC
  4. Millennium Management LLC
  5. Renaissance Technologies LLC
  6. Two Sigma Investments LP
  7. Walleye Capital LLC
  8. BNP Paribas Financial Markets
Within the last year, these company insiders have bought INmune Bio stock:
  1. Raymond Joseph Tesi (CEO)
  2. David J Moss (CFO)
  3. Timothy J Schroeder (Director)
Learn More investors buying INmune Bio stock.